Overexpression of thymosin β10 correlates with disease progression and poor prognosis in bladder cancer

Wang,Bingwei; Wang,Zhenwei; Zhang,Tao; Yang,Guosheng

doi:10.3892/etm.2019.8006

Overexpression of thymosin β10 correlates with disease progression and poor prognosis in bladder cancer

Authors:
- Bingwei Wang
- Zhenwei Wang
- Tao Zhang
- Guosheng Yang
View Affiliations

Affiliations: Department of Urology, The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510317, P.R. China, Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong 510317, P.R. China
Published online on: September 13, 2019 https://doi.org/10.3892/etm.2019.8006
Pages: 3759-3766
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymosin β10 (TMSB10) has been found to be overexpressed and function as an oncogene in several types of cancer. However, there have been limited reports on the role of TMSB10 in bladder cancer (BCa). In the present study, reverse transcription‑quantitative PCR was used to quantify the expression of TMSB10 in BCa cell lines, clinical specimens and their corresponding control samples. The protein expression of TMSB10 was also examined in archived tissues from 101 patients with pathologically confirmed BCa by immunohistochemistry. Univariate and multivariate Cox regression models were used to evaluate the prognostic significance of TMSB10 in patients with BCa. The data indicated that the mRNA levels of TMSB10 were significantly overexpressed in BCa cell lines. In addition, the protein levels of TMSB10 were overexpressed in BCa tissues compared with those in adjacent normal tissues. In 55/101 (54.5%) BCa specimens, high expression levels of TMSB10 were noted. Statistical analysis revealed that the high expression of TMSB10 was positively associated with muscular invasion (P<0.05). In addition, a high expression of TMSB10 was associated with shorter overall survival (OS) of patients (P<0.05; log‑rank test). The univariate and multivariate analyses suggested that the protein overexpression of TMSB10 was an unfavorable prognostic factor for OS (P<0.05) in patients with BCa. Knockdown of the expression of TMSB10 significantly suppressed cell migration and invasion. In conclusion, TMSB10 can be considered an independent factor for the poor prognosis of patients with BCa. The targeting of TMSB10 can reduce the migration and invasion of BCa cells.

View Figures

View References

1	Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 71:96–108. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
4	Bellmunt J and Petrylak DP: New therapeutic challenges in advanced bladder cancer. Semin Oncol. 39:598–607. 2012. View Article : Google Scholar : PubMed/NCBI
5	Goldstein AL, Slater FD and White A: Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 56:1010–1017. 1966. View Article : Google Scholar : PubMed/NCBI
6	Erickson-Viitanen S, Ruggieri S, Natalini P and Horecker BL: Thymosin beta 10, a new analog of thymosin beta 4 in mammalian tissues. Arch Biochem Biophys. 225:407–413. 1983. View Article : Google Scholar : PubMed/NCBI
7	Weterman MA, van Muijen GN, Ruiter DJ and Bloemers HP: Thymosin beta-10 expression in melanoma cell lines and melanocytic lesions: A new progression marker for human cutaneous melanoma. Int J Cancer. 53:278–284. 1993. View Article : Google Scholar : PubMed/NCBI
8	Oien KA, Vass JK, Downie I, Fullarton G and Keith WN: Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene. 22:4287–4300. 2003. View Article : Google Scholar : PubMed/NCBI
9	Zhang X, Ren D, Guo L, Wang L, Wu S, Lin C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer. Breast Cancer Res. 19:152017. View Article : Google Scholar : PubMed/NCBI
10	Liu CR, Ma CS, Ning JY, You JF, Liao SL and Zheng J: Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl). 117:213–218. 2004.PubMed/NCBI
11	Theunissen W, Fanni D, Nemolato S, Di Felice E, Cabras T, Gerosa C, Van Eyken P, Messana I, Castagnola M and Faa G: Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. Eur J Histochem. 58:22422014. View Article : Google Scholar : PubMed/NCBI
12	Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K and Amino N: Quantitative analysis of thymosin beta-10 messenger RNA in thyroid carcinomas. Jpn J Clin Oncol. 32:229–232. 2002. View Article : Google Scholar : PubMed/NCBI
13	Califano D, Monaco C, Santelli G, Giuliano A, Veronese ML, Berlingieri MT, de Franciscis V, Berger N, Trapasso F, Santoro M, et al: Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res. 58:823–828. 1998.PubMed/NCBI
14	Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q and Chen C: Advances in thymosin beta10 research: Differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest. 27:1016–1022. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sribenja S, Wongkham S, Wongkham C, Yao Q and Chen C: Roles and mechanisms of β-thymosins in cell migration and cancer metastasis: An update. Cancer Invest. 31:103–110. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sobin LH, Gospodarowicz MK and Wittekind C: International against cancer (UICC). TNM classification of malignant tumours. 7th edn. New York. Wiley2009.
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
19	Lee SH, Zhang W, Choi JJ, Cho YS, Oh SH, Kim JW, Hu L, Xu J, Liu J and Lee JH: Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene. 20:6700–6706. 2001. View Article : Google Scholar : PubMed/NCBI
20	Lee SH, Son MJ, Oh SH, Rho SB, Park K, Kim YJ, Park MS and Lee JH: Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res. 65:137–148. 2005.PubMed/NCBI
21	Gu Y, Wang C, Wang Y, Qiu X and Wang E: Expression of thymosin beta10 and its role in non-small cell lung cancer. Hum Pathol. 40:117–124. 2009. View Article : Google Scholar : PubMed/NCBI
22	Zhang XJ, Su YR, Liu D, Xu DB, Zeng MS and Chen WK: Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma. J Surg Res. 192:487–493. 2014. View Article : Google Scholar : PubMed/NCBI